Home hemodialysis device developer Outset Medical raises $60 million for its Tablo dialysis system.
Ablative Solutions wins CE Mark approval in the European Union for its Peregrine infusion ablation catheter for treating uncontrolled hypertension.
Ablative Solutions said it received CE Mark approval for its Peregrine infusion ablation catheter for treating uncontrolled hypertension. The company began testing Peregrine last year in Poland.
Medtronic says it's launching a clinical trial evaluating renal denervation and cardiac ablation in treating atrial fibrillation.
Medtronic (NYSE:MDT) today said it's launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation.
Boston Scientific launches a clinical trial of its Vessix renal denervation device in treating hypertension, aiming to separate its effects from drug therapy for high blood pressure.
ReCor Medical raises a $15 million Series D financing for a planned U.S. study of its ultrasound renal denervation device.
A Japanese healthcare conglomerate is the lead investor ReCor Medical's $15 million Series D round ReCor plans to use to back a U.S. clinical trial of its ultrasound renal denervation device.
Baxter International wins CE Mark approval in the European Union for its HomeChoice Claria device for home peritoneal dialysis treatments.
Medtronic launches a new clinical trial examining renal denervation as a treatment for hypertension, aiming to settle the 'confounding factors' that led to the failure of its Symplicity-3 trial.